Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series

Relapsed or refractory (R/R) large B cell lymphoma (LBCL) presenting as secondary central nervous system lymphoma (SCNSL) carries a poor prognosis, with a median survival time of two to five months. Chimeric antigen receptor (CAR)-T cell therapy has been approved in R/R LBCL, but studies are ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhaliwal, Armaan, Mann, Shivtaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568653/
https://www.ncbi.nlm.nih.gov/pubmed/37842456
http://dx.doi.org/10.7759/cureus.45088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568653/
https://www.ncbi.nlm.nih.gov/pubmed/37842456
http://dx.doi.org/10.7759/cureus.45088

Ejemplares similares